Hepagene Therapeutics (Hk) Limited

Calculating rank

USPTO Granted Patents = 6

% Expired Patents = 16.7

Forward Citations = 0

Loading Chart...

6 inventors (with patents filed for the assignee):

Xiaodong Xu (4 out of 19 patents)

Ben Li (1 out of 3 patents)

Xiaodong Xu (1 out of 1 patent)

4. Shijia Chen (1 out of 1 patent)

5. Shanghai Yu (1 out of 1 patent)

6. Cheng Mo (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 12780816 - Solid forms of a benzthiazole-piperazinyl-oxazole compound and methods of use thereof (2026-11-03),

2. 12760066 - Bivalent antagonists of inhibitors of apoptosis proteins (2026-10-13),

3. 12378268 - Heterocyclic THR-β receptor agonist compound and preparation method and use therefor (2025-08-05),

4. 11427556 - Urea derivatives as inhibitors of ASK1 (2022-08-30),

5. 10919903 - Nitrogen-containing heterocyclic compounds as FXR modulators (2021-02-16),

6. 10899723 - Heterocyclic containing cyclopropyl FXR modulators (2021-01-26),

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

6 Patents

#508 in Hong Kong

#4,489 in China

Hong Kong, China

Hepagene Therapeutics (Hk) Limited

Forward Citations = 0

6 inventors:

Xiaodong Xu (4 out of 19 patents)

Ben Li (1 out of 3 patents)

Xiaodong Xu (1 out of 1 patent)

4. Shijia Chen (1 out of 1 patent)

5. Shanghai Yu (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hepagene Therapeutics (Hk) Limited. Retrieved from https://idiyas.com/company/hepagene-therapeutics-hk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]